The Food and Drug Administration has approved a new, first-of-its-kind semiannual HIV prevention medication, Gilead Sciences ...

The US Food and Drug Administration (FDA) has approved a new shot to prevent HIV, offering a long-acting alternative to daily ...

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

The recent FDA approval of lenacapavir is encouraging in its promise of long-term HIV prevention but might not be available for the vast majority of people in the US.

How an Indian contract manufacturer will establish a biotech foothold in the U.S.

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

Winnie Byanyima says her organization has lost almost 50% of its funding, a gap that is undermining global efforts to combat ...

FRIDAY, June 20, 2025 (HealthDay News) — A new shot to prevent HIV infection has just been approved — and it only needs to be ...

Patients with HIV receiving 3-drug ART with BIC/FTC/TAF exhibited low rates of viremia, particularly those with high treatment adherence.

The US Food and Drug Administration approves Wednesday, June 18, Gilead Sciences lenacapavir, a twice-yearly injection, for ...

And more pharma news updates from Pharmalittle.